Serious Gaming for Chemotherapy-induced Nausea and Vomiting

Sponsor
University of Central Florida (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05838638
Collaborator
Orlando Health, Inc. (Other), University of Miami (Other), National Institute of Nursing Research (NINR) (NIH)
610
2
50

Study Details

Study Description

Brief Summary

The purpose of this study is to examine the effectiveness of a technology-based intervention for managing nausea and vomiting in older adults with cancer. Participants will be randomized to either an intervention or control group. Outcomes such as symptom severity, quality of life, and resource use will be examined.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: eSSET-CINV
N/A

Detailed Description

The goal of this study is to increase the use of preventative self-management behaviors for nausea and vomiting in older adults receiving chemotherapy to reduce negative outcomes and emergency or hospital admissions. Early reinforcement of standard education and re-framing any preconceived beliefs about the ability of nausea and vomiting to be managed will increase preventative self-management behaviors and improve patient outcomes. Participants will be in the study for 6 chemotherapy treatment cycles. This could be 12 to 24 weeks depending on if they receive treatment every 2, 3 or 4 weeks.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
610 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants will be randomly assigned to either an intervention or control group.Participants will be randomly assigned to either an intervention or control group.
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Serious Gaming for Chemotherapy-induced Nausea and Vomiting in Older Adults With Cancer: A Randomized Clinical Trial
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Jun 30, 2027
Anticipated Study Completion Date :
Jun 30, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

This intervention is a serious game which allows older adults under treatment for cancer to practice making self-care decisions for an avatar that is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with the research assistant about choices related to managing nausea and vomiting at home

Behavioral: eSSET-CINV
Participants in the intervention group will be asked to play the serious game on an iPad at their first chemotherapy treatment visit. The control group will be able to play at time 6.
Other Names:
  • Managing at Home- CINV
  • Active Comparator: Control

    The control group will receive standard education related to managing nausea and vomiting and will have the opportunity to participate in the intervention at the end of the study

    Behavioral: eSSET-CINV
    Participants in the intervention group will be asked to play the serious game on an iPad at their first chemotherapy treatment visit. The control group will be able to play at time 6.
    Other Names:
  • Managing at Home- CINV
  • Outcome Measures

    Primary Outcome Measures

    1. Healthcare resource use [From baseline through the end of the study at 12 or 24 weeks]

      any emergency department or hospital admission will be recorded using a dichotomous variable (yes/no)

    2. CINV severity [From baseline1 through the end of the study at 12 or 24 weeks]

      The Symptom Management Checklist will measure the presence and severity of nausea and vomiting. Participants will be sent a text link every day for 6 days after chemotherapy or complete this data on a form at home. This starts right after time 1. Nausea will be reported on a 0-10 scale. Higher numbers equal more nausea.

    Secondary Outcome Measures

    1. Self-management behaviors [From baseline through the end of the study at 12 or 24 weeks]

      The Symptom Management Checklist will measure self-management behaviors and preventive behaviors for CINV. Participants will be sent a text link every day for 6 days after chemotherapy or complete this data on a form at home. This starts right after Time 1.

    2. Symptom severity [Baseline and 12 or 24 weeks]

      The Symptom Representation Questionnaire Part 1 is a 24 item self-report measure that will be used to identify the presence and severity of common treatment-related side effects (0 to 10 scale). Higher numbers indicate more severe symptoms. This measure asks participants to think about their symptoms over the last week

    3. Cognitive representation [Baseline and 12 or 24 weeks]

      The Symptom Representation Questionnaire Part 2 has 15 questions related to cognitive beliefs about nausea. Sub scales examine symptom cause, timeline, cure/control, and consequences. An agreement type Likert scale is used.

    4. Health-related Quality of Life [baseline, 4,8,12,16,20, and 24 weeks]

      The EORTC-30 will measure quality of life at each treatment cycle. Higher scores mean better quality of life

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    60 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • age 60 or older

    • newly diagnosed with cancer

    • treatment with any chemotherapeutic agent of moderate or high emetic potential

    • on a 2, 3 or 4 week treatment cycle

    • proficient in English

    • has a telephone

    Exclusion Criteria:
    • previous diagnosis and/or treatment for cancer

    • end stage disease with less than 6 months to live

    • visually or hearing impaired without corrective device

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University of Central Florida
    • Orlando Health, Inc.
    • University of Miami
    • National Institute of Nursing Research (NINR)

    Investigators

    • Principal Investigator: Victoria Loerzel, PhD, University of Central Florida

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University of Central Florida
    ClinicalTrials.gov Identifier:
    NCT05838638
    Other Study ID Numbers:
    • 00003808
    • R01NR020003
    First Posted:
    May 1, 2023
    Last Update Posted:
    May 6, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Central Florida
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 6, 2023